Net sales in Q2 came in slightly lower than our forecast. However, lower than expected operating expenses and no sales of durable goods resulted in a significantly higher profitability than what we had anticipated. We have a positive view of the report, but believe that a surge in sales related to warm perfusion will happen slightly later than what we had previously accounted for.